Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...

The only potentially curative options for gastric cancer involve endoscopic or surgical resection, with adjunctive systemic ...

The biotech company shared encouraging clinical data at the oncology conference, showing sustained complete response lasting ...

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after ...

The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.

Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), ...

In evaluable patients, IMC002 achieved an objective response rate (ORR) of 66.7% (10/15). Survival data were immature at the time of analysis, with a median progression-free survival (mPFS) of 7.0 ...

ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma. Among patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, those ...

Arcus Biosciences Inc. provided an update on the phase III Star-221 study conducted in partnership with Gilead Sciences Inc., saying the trial will stop due to futility. Star-221 was designed to test ...

Unfortunately you've used all of your gifts this month. Your counter will reset on the first day of next month.

HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific ...

SHANGHAI, Oct. 9, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that its self-developed innovative anti-PD-1 monoclonal antibody, HANSIZHUANG (serplulimab, Hetronifly ® in ...